Search

Introduction and Objective. Every year, 20 million people are diagnosed with cancer, most of whom undergo chemotherapy at some stage of treatment. Chemotherapy is associated with various side effects, with hair loss being one of the most visible and socially stigmatizing. This study aimed to evaluate and summarize existing strategies for preventing chemotherapyinduced hair loss. Review methods: Data for this paper were gathered using electronic databases like PubMed and Google Scholar, with a focus on papers from the last five years, particularly clinical trials, double-blind randomized studies, meta-analyses, and reviews. State of Knowledge: Around 65% of chemotherapy patients experience hair loss. Currently, the FDA has approved one method for preventing chemotherapy-induced alopecia (CIA): scalp cooling. This technique induces localized vasoconstriction, reducing the penetration of chemotherapy drugs into hair follicles. Scalp cooling is generally well-tolerated. Other potential methods include scalp injections of autologous platelet-rich plasma, which contains growth factors and anti-inflammatory cytokines, and microneedling, an invasive procedure with uncertain effectiveness, especially as a standalone treatment, that aims to stimulate angiogenesis. Conclusions: Effective, reliable methods for preventing chemotherapy-induced alopecia (CIA) are still lacking. A holistic approach to oncology care is needed to address the diverse needs of patients. Discovering new preventive methods would greatly improve patients' ability to cope with cancer treatment. However, most current approaches show only moderate efficacy or are still in clinical trials. [ABSTRACT FROM AUTHOR]

Introduction and aim. Congenital heart block in fetus may occur when pregnant woman suffers from an autoimmune disease. The placenta transfers maternal antibodies specific for Ro and La autoantigens. The heart of fetus, which is anatomically correct, does not work in the proper way. The electrical conduction system of the heart is being inflamed, therefore it leads to electric signal detainment. This disorder is rare, and in every case it may be divergent and conduct to various manifestations. Description of the case. We present the course of medical diagnosis of a woman who is 29 years old, in her second pregnancy. Before gestation she didn't have a previous history of an rheumatic illness. Her laboratory results showed a high level of antibodies Ro and La, she had typical symptoms for an autoimmune disease. The fetus was diagnosed with bradycardia and first degree heart block at the 28th week of pregnancy. Conclusion. There is a popular opinion that all autoimmune diseases are always becoming muted during pregnancy. This case report is the exception to this rule. A characteristic manifestation of this autoimmune disease led to the correct diagnosis and proper therapy. [ABSTRACT FROM AUTHOR]